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Background: Acute exacerbation is a common cause of hospitalization in patients with chronic heart failure, and
coronary heart disease is the most common cause. Shenfu injection, a Traditional Chinese Medicine injection,
widely used in the adjuvant treatment of patients with acute exacerbation of chronic heart failure, shows some
treatment effect in improving the symptoms and the quality of life, but it lacks the rigorous clinical evaluation of
research reports. This paper describes the protocol for the clinical assessment of Shenfu injection loading in the
treatment of patients with acute exacerbation of chronic heart failure.
Methods: This protocol adopts the design of a prospective, randomized, multicenter, blind imitation, placebo-controlled
trial to assess the efficacy and safety of Shenfu injection loading in the treatment of patients with acute exacerbation
of chronic heart failure due to coronary heart disease. The research will be carried out in 12 hospitals in China
and is expected to enroll 160 inpatients with acute exacerbation of chronic heart failure due to coronary heart
disease (yang and qi deficiency syndrome). On the basis of the conventional therapy of western medicine, patients will
be randomized to either the treatment group (100 ml 5% glucose injection + 50 ml Shenfu injection) or the control
group (150 ml 5% glucose injection) for 7 ± 1 days and follow-up for 28 ± 3 days. The primary outcomes are New York
Heart Association cardiac function classification and Traditional Chinese Medicine syndromes. The secondary outcomes
are left ventricular ejection fraction, brain natriuretic peptide level, Lee’s heart failure score, 6-minute walking distance,
and the incidence and readmission rate of cardiovascular events (including the emergency rate due to acute
exacerbation of chronic heart failure).
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Discussion: This trial will assess the effect of loading Shenfu injection in the treatment of patients with acute
exacerbation of chronic heart failure caused by coronary heart disease (yang-qi deficiency syndrome) on the
symptoms and signs of heart failure, exercise tolerance, and other aspects, and observe its influence on the
short-term prognosis with follow-up. The results of the study will provide clinical research evidence for application
of Shenfu injection in the treatment.
Trial registration: This trial was registered on 26 December 2012 at the Chinese Clinical Trials Register (Identifier:
ChiCTR-TRC-12002857).
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Chronic Heart failure (CHF) is a chronic progressive dis-
ease, the terminal stage of various cardiovascular diseases
and a cardiac dysfunction syndrome. The condition of
CHF patients will remain stable after treatment, but
will also dramatically worsen under the influence of
various factors (such as infection, rapid ventricular rate
arrhythmia, and so forth) and appears as acute decom-
pensated CHF (that is, acute exacerbation of CHF
(AECHF)) [1].
The first guideline for diagnosis and treatment of
acute heart failure (AHF) in China was promulgated in
March 2010 [2]. “AHF” referred to sudden onset or
acute exacerbation of the original CHF, expanding the
scope of AHF, and acute decompensation of CHF was
included. The diagnosis and treatment guideline for
heart failure of China in 2014 [3] indicates that AHF is
the main cause of hospitalization in patients whose age
has exceeded 65 years, most of them with acute exacer-
bation based on the original CHF.
A study [4] which retrospectively analyzed 10,714 hospi-
talized cases retrieved from 42 hospitals in China over
three different time periods (the 1980s, 1990s, and 2000s)
showed that patients hospitalized for CHF accounted for
about 16.3 to 17.9% of those with cardiovascular disease.
The primary cause of CHF was coronary heart disease
(CHD), most of the cardiac function of HF was grade
III(42.5 to 43.7%),and the main cause of death in heart
failure patients was left heart failure (59%).
The treatment for AECHF, according to the guideline
[3], which is the same as the treatment for AHF, in-
cludes: general treatment (such as oxygen therapy, con-
trolling the intake and output, and so forth); medical
treatment (such as diuretics which can reduce cardiac
load and improve symptoms); treatment with drugs or/
and non-drug therapy for the main disease and compli-
cations depending on patient’s conditions. The symp-
toms of AECHF can be alleviated over a short period
using simple western medicine treatment, shown by im-
provement in heart function, hemodynamic indices and
biological indices. Presently, Traditional Chinese Medi-
cine (TCM) treatment for AECHF is still secondary towestern medicine, and TCM injection, such as Shenfu
injection (SFI) [5] and Shenmai injection [6] ,are com-
monly used by TCM syndrome.
A retrospective study [7] showed that the main TCM
syndrome of CHF was deficiency of qi, with yang or/and
yin. The result of a TCM syndrome survey [8] showed
that CHF was divided into two types: qi-yang deficiency
with blood stasis and/or phlegm retention; and qi-yin
deficiency with blood stasis and/or phlegm retention.
The pattern of syndrome change [9] was qi deficiency →
qi deficiency, qi-yin deficiency →qi-yang deficiency with
blood stasis and/or phlegm retention.
Based on the ancient prescription of Shenfu Decoc-
tion, SFI is composed of the extracts of red ginseng and
Radix Aconiti Lateralis Preparata using modern technol-
ogy. The active ingredients include Ginsenoside and
Aconitine [10], which have the function of supplement-
ing qi, avoiding collapse and reviving yang. SFI was an
officially approved product in 1987 (approval code: certi-
fication number Z20043117; norm: 50 ml per bottle).
Many clinical reports indicated that SFI was convenient
for emergency use and had the advantages of rapid effect
[11], strengthening the heart, improving heart function,
protecting vascular endothelial cells, regulating immune
function, anti-inflammation and improving ability of
hypoxia tolerance [12].Objective
The objective of this trial is to observe the influence of
heart function and TCM syndrome and to assess the
short-term effectiveness and safety in patients with AECHF
due to CHD (yang-qi deficiency syndrome) treated with
SFI loading.Methods
Study design
This study is a prospective, randomized, multicenter,
blind imitation, placebo-controlled trial. In order to
avoid regional differences, participating centers include
12 hospitals located in the north and south of China. All
cases included are hospitalized patients. Totally 160
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trol groups. The specific scheme is shown in Figure 1.
Sample size
This is a clinical pilot trial; therefore, the total sample
size of this study is determined to be 160 (during the
trial, the expulsion rate is controlled within 20%) on ex-
pert advice. The treatment group and the control group
have the same number of cases (that is, there are 80
cases in each group).
Diagnostic criteria
Diagnostic criteria for coronary heart disease
The diagnostic criteria for CHD were: 1) history of myo-
cardial infarction, with or without revascularization
(percutaneous coronary intervention or coronary artery
bypass grafting) treatment; and/or 2) coronary angiog-
raphy or computed tomography coronary angiography
confirmation of stenosis above 50% of at least one major
branch of the coronary artery luminal diameter, with or
without revascularization. A patient with one of these
criteria is to be diagnosed with CHD.Figure 1 Schedule of evaluations. The overall plan of the trial and each
SFI, Shenfu injection; GLI, glucose injection; NYHA, New York Heart Associat
fraction; BNP, brain natriuretic peptide; 6MWD, 6-minute walking distance.Diagnostic criteria for acute exacerbation of chronic heart
failure
According to The diagnosis and treatment guideline for
CHF of China in 2007 [13], The diagnosis and treatment
guideline for AHF of China in 2010 [2], Executive Sum-
mary: HFSA 2010 Comprehensive Heart Failure Practice
Guideline [14], the diagnostic criteria for AECHF were:
1) having a medical history, symptoms or signs of heart
disease, and the main symptoms and signs of dyspnea,
fatigue, fluid retention (edema), jugular venous engorge-
ment, and so forth; and 2) left ventricular ejection frac-
tion (LVEF) ≤40% by the Simpson method.
Diagnostic criteria for cardiac function classification
Referring to the New York Heart Association updated
version in 2005 [15], the criteria for heart functional
class III were that the patients suffer from heart disease,
and physical activity is significantly restricted (fatigue,
palpitation, dyspnea or angina pectoris when the activity
amount is less than normal), and for heart functional
class IV that the patients suffer from heart disease, and
physical activity is completely lost (symptoms of heartstep that needs to be performed is listed. CHF, chronic heart failure;
ion; TCM, Traditional Chinese Medicine; LVEF, left ventricular ejection
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any slight physical activity can make symptoms worse,
for example dyspnea and fatigue).
The standardization of Traditional Chinese Medicine
differentiation
According to The Guidelines for Clinical Research of
new TCM drugs (2002) [16,17], the primary signs and
symptoms are palpitation, shortness of breath (dyspnea),
and fatigue. The secondary signs and symptoms are
spontaneous perspiration, disinclination to talk, wheez-
ing, cough, chest stuffiness (pain), loss of appetite, ab-
dominal distension, aversion to cold, cold limbs, and
edema. In addition, the tongue and pulse presentation is
of a pale and dark tongue, which is fat or with indenta-
tion, and the pulse is sunken, slow or quick, or knotted
and intermittent.
A patient must meet all the primary symptoms and at
least two of the secondary symptoms listed above, con-
sulted with the tongue and pulse presentation, to be di-
agnosed with yang-qi deficiency syndrome.
Inclusion criteria
(1) Patients aged 40 to 79 years;
(2) Diagnosis of CHD, AECHF;
(3) New York Heart Association Class II to IV;
(4) TCM diagnosis of yang- qi deficiency syndrome;
(5) Provision of written informed consent by
participants or surrogates.
Exclusion criteria
(1) Patients with acute coronary syndrome (cardiac
troponin T/ cardiac troponinI, creatine kinase-MB
isoenzyme as screening index, acute myocardial
infarction within 6 months, revascularization within
the past 6 months or planned for revascularization
within 1 week after inclusion, cardiogenic shock,
lethal arrhythmia, cardiomyopathy, rheumatic
valvular heart disease, myocarditis, constrictive
pericarditis, pulmonary embolism, and so forth.
(2) Severe hepatic, renal insufficiency (alanine
transaminase ≥3 times the normal upper limit,
creatinine ≥3 mg/dL;
(3) Combined with the endocrine system, hematopoietic
system and other severe primary diseases;
(4) Preparing for pregnancy within 3 months, pregnant,
or breast-feeding women;
(5) Patients with psychosis;
(6) Patients with an allergic constitution, known
sensitivity to the study drugs or their ingredients;
(7) Participation in other clinical trials within 3
months;(8) Researchers estimate that the survival period of
patient is not more than 3 months;
(9) Researchers estimate that the patient cannot complete
or comply with the requirements of this study.
Randomization
This study will use the central randomization system of
the Tianjin Institute of Clinical Evaluation to achieve the
distribution of patients and drugs.
The central randomization system will adopt age (40
to 49, 50 to 59, 60 to 69, and 70 to 79 years) and cardiac
function classification as the central random control fac-
tors to dynamically and randomly allocate the partici-
pants, keeping a balance between the two groups to
avoid selection bias; it will also monitor the real-time
drug distribution and inventory information of each cen-
ter in order to timely supply drugs and effectively avoid
drug excess, saving the resources of manpower and
materials.
Blindness
Because SFI is a colored transparent liquid, nurses use
the disposable light-proof infusion cover to effectively
block the test drug and 5% glucose injection (GLI) in
order to reduce bias. This study will blind doctors,
evaluators, patients and statistical experts, but not the
nurses.
Interventions
According to The diagnosis and treatment guideline for
AHF of China in 2010 [2] and The diagnosis and treat-
ment guideline for CHF of China in 2007 [13], doctors
will choose medications based on conventional Western
medicine treatment, and are prohibited from using other
TCM in addition to the test drug. Combined with the
cardiac function of patients, the basal therapy for CHF
and AECHF are as follows: diuretics (furosemide injec-
tion for the first 7 ± 1 days and oral tablet during the
follow-up period), angiotensin-converting enzyme inhib-
itors or angiotensin receptor blockers, β-blockers, aldos-
terone antagonists, digitalis, anti-platelet drugs, statin
drugs, and so forth.
In order to reduce the bias of the test results, the con-
trol group is treated with 150 ml 5% GLI. The injection
volume for the control group is therefore the same as
the treatment group. All patients need to have a fasting
blood glucose test and diabetic patients have to adjust
the dose of insulin before participating in the trial.
The test drug is used as follows. For the treatment
group: 50 ml SFI dissolved in 100 ml 5% GLI delivered
via intravenous drip within 150 minutes, once a day; for
the control group: 150 ml 5% GLI via intravenous drip
within 150 minutes, once a day; both over 7 ± 1 days as
a course.
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Primary outcomes
The primary outcomes of the study include the effective
rate on the improvement of heart functional class and
TCM syndrome. TCM syndrome is evaluated by grading
the quantitative score according to the primary symptoms
and secondary symptoms. Two indices, which are mea-
sured before and after treatment, are simple measurements
used to judge the degree of CHF. The severity of heart fail-
ure symptoms has a poor correlation with ventricular func-
tion, but is clearly associated with survival rate [3].Secondary outcomes
Combined with physical and chemical examinations pre-
and post-treatment, changes in objective indices are
used to evaluate the therapeutic effect.
LVEF and other echocardiographic indices reflect left
ventricular function. In view of the correlation between
left ventricular volume, LVEF and angiography on aut-
opsy, the trial uses the modified Simpson method to
measure echocardiographic indices, and the relevant
standard operating procedure is presented in the investi-
gator’s manual.
The plasma brain natriuretic peptide (BNP) level can
be used as an auxiliary method to evaluate the treatment
efficacy. Test instruments(Biosite Triage ® MeterPlus)
will be unified to avoid measurement error.
The trial will combine the symptoms and signs with
X-ray cardiac telephotography examination for assess-
ment of Lee’s heart failure score.
Six-minute walking distance is measured within 24
hours after inclusion and also after treatment to evaluate
the change in exercise tolerance. At the same time, the
trial also observes the occurrence of end-point events,
and analyzes the incidence and readmission rate for car-
diovascular events.Safety outcomes
Safety is assessed by vital signs, laboratory examinations
and adverse events. Vital signs include blood pressure
and heart rate. Laboratory examinations include routine
blood and urine, routine stool and fecal occult blood,
hepatorenal function, electrolytes and electrocardiogram.
The purpose of examining routine stool and fecal occult
blood is to prevent gastrointestinal hemorrhage because
of the treatment with antiplatelet aggregation, anticoa-
gulant drug. The purpose of examining electrolytes (K+,
Na+, Cl−) is to prevent electrolyte disorder for heart fail-
ure treatment with diuretics.
Adverse events will be recorded during the treatment.
The prognosis of adverse events will also be observed
until the adverse reactions disappear or are relieved.Data collection
We will collect basic information (gender, age, previous
history, medication and so forth), disease severity assess-
ment (heart functional class, TCM syndrome score, Lee’s
heart failure score, 6-minute walking distance), and phys-
ical and chemical examinations (echocardiogram, BNP
and so forth); specific items and study visits are shown in
Figure 2.
Data information will be separately filled in the study
medical record and the case report form by researchers.
The study medical record is designed to be convenient
for the researchers. Based on the need for data traceabil-
ity, the study medical record preserves original informa-
tion, such as the patient’s name, contact information, the
results of physical and chemical examinations and so
forth. The design of the case report form is convenient
for data entry. The patients are distinguished by code,
and their personal and private information will not be
shown.
Statistical analysis
Statistical analysis will be performed by the Tianjin Insti-
tute of Clinical Evaluation, and the data will be analyzed
using Statistical Analysis System (SAS) software version
9.3 (SAS Institute Inc., Cary, NC, USA). Data sets for
efficacy assessment will follow the intention-to-treat
principle. Continuous variables will be described using
mean and standard deviation and tested by t tests. Cat-
egorical variables will be presented using percentages
and tested by chi-squared test. More details will be de-
scribed in a formal statistical analysis plan.
Ethical issues
This trial protocol was approved by the Ethics Commit-
tee of the First Teaching Hospital of Tianjin University
of TCM (TYLL2012 [K] 003) and other Institutional Re-
view Boards of participating hospitals (the names of all
ethical bodies can be found in Additional file 1). The
study protocol and informed consent are consistent with
scientific and ethical requirements. Written informed
consent must be obtained from all participants or their
legally authorized representatives before enrollment.
Discussion
The efficacy of integrative treatment for AECHF with
TCM and western medicine has been gradually accre-
dited with improving symptoms, signs, quality of life, ex-
ercise tolerance, long-term prognosis (reducing mortality
and readmission rate of CHF), and so forth, and has
been demonstrated in clinical studies [18,19].
As a post-marketed herbal species used for nearly 30
years, the composition of SFI is clear and its quality is
reliable. Some clinical reports showed that the conven-
tional western medicine combined with SFI could further
Figure 2 The trial flow chart. The work at each point of time is listed. cTnT, cardiac troponin T; cTnI, cardiac troponinI; CK-MB, creatine kinase-MB
isoenzyme; NYHA, New York Heart Association; TCM, Traditional Chinese Medicine ; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide;
6MWD, 6-minute walking distance; FBG, fasting blood glucose; ECG, electrocardiogram; CRF, case report form.
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the quality of life and show a clinical curative effect, in-
crease LVEF and decrease left ventricular end-diastolic
diameter [20], reduce plasma BNP and cytokine Fas,
tumor necrosis factor-α, and interleukin-6 levels, as well
as mobilize the function of bone marrow stem cell [21,22].Some research revealed that SFI could attenuate post-
resuscitation myocardial dysfunction by increasing the en-
zyme activity on Na+-K+-ATP and Ca2+-ATP of the left
ventricle [23], increasing superoxide dismutase and de-
creasing malondialdehyde, promoting energy metabolism
and anti-oxidative damage.
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(1) Selection of patients with AECHF due to CHD; this
is a specific disease group and a study on the primary
cause and the main type of hospitalization. (2) This is a
superiority trial comparing a study drug with placebo. In
view of the external characteristics of TCM injection,
the study uses the method of blind imitation, with an
intravenous drip of 5% GLI with a light-proof infusion
cover. (3) The effective rate of heart functional class and
TCM syndrome are primary outcomes; it will adopt the
clinical effect evaluation methods of “the combination of
disease and syndrome, systematic staging, multi-dimension
index” [24], and will select indices that reflect both the ad-
vantages and characteristics of TCM and the conventional
efficacy evaluation of western medicine, and observation of
the incidence of end-point events. In addition, the drug
dosage of the test group was decided upon through litera-
ture research [25] and taken to be 50 ml SFI dissolved in
100 ml 5% GLI via intravenous drip within 150 minutes, in
order to relieve cardiac load as much as possible.
Trial status
The trial was initiated in March 2013. Now, the study is
in the stage of database testing and is ready to data input
and statistics. The completion date of trial is estimated
at December 2015.
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